On June 17, 2025, Plus Therapeutics Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, committing Lincoln Park to purchase up to $50 million of the company's common stock. The share price for transactions under this agreement may vary, but the agreement includes provisions for a purchase price per share in an Accelerated Purchase to be 96.5% of the lower of specified market prices. The specific number of shares and exact prices for these transactions were not disclosed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.